Valink Therapeutics Inc. is a biotechnology company developing first-in-class bispecific antibody-drug conjugates (bsADCs) and other modalities for improved patient outcomes. Valink’s proprietary discovery platform and V-gate™ approach address key challenges of current technologies by expanding the toolbox of available approaches for bispecific antibody therapeutics and bispecific ADCs, unlocking fine-tuned target control, functional outcomes, and improved therapeutic index.
Leadership & Board
Current Number of Employees31
Current LinkedIn Followers3,854
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$12M
Total Amount Raised$12M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$12M
Latest Funding Amount$12M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Valink Therapeutics had 31 employees as of October 5, 2026. The number of employees increased by 0 (0.00%) week-over-week.
31Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Valink Therapeutics had 3,854 followers as of October 5, 2026. The number of followers increased by 8 (0.21%) week-over-week.
3,854Latest Followers Count
8(0.21%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.